Treatment of cognitive deficits in schizophrenia - Part 2: Pharmacological strategies

被引：5

作者：

Roesch-Ely, D. ^{[2
]}

Pfueller, U. ^{[1
,2
]}

Mundt, C. ^{[2
]}

Mueller, U. ^{[3
]}

Weisbrod, M. ^{[1
,2
]}

机构：

[1] SRH Klinikum Karlsbad Langensteinbach, Klin Psychiat & Psychotherapie, Karlsbad, Germany

[2] Univ Klinikum Heidelberg, Klin Allgemeine Psychiat, Zentrum Psychosoziale Med, D-69115 Heidelberg, Germany

[3] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 1TN, England

来源：

NERVENARZT | 2010年 / 81卷 / 05期

关键词：

Cognition-enhancing drugs; Cognition; Schizophrenia; Psychopharmacology; Treatment; RANDOMIZED CONTROLLED-TRIAL; WORKING-MEMORY; DOUBLE-BLIND; ANTIPSYCHOTIC-DRUGS; 1ST-EPISODE SCHIZOPHRENIA; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; ADD-ON; DOPAMINERGIC MODULATION; RECEPTOR ANTAGONIST;

D O I：

10.1007/s00115-009-2919-6

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Cognitive deficits in schizophrenia are a clinically relevant symptom dimension and one of the best predictors for functional outcome. Pharmacological treatment of cognitive deficits in schizophrenia is still a challenge. The objective of this article is to present a detailed review of the literature on strategies for the pharmacological treatment of cognitive deficits. It is not clear whether first-generation antipsychotics have a genuine positive influence on cognition. There is only sparse evidence for the positive effect of second-generation antipsychotics on cognitive processes. Furthermore it is not evident that second-generation antipsychotics are more beneficial than first-generation antipsychotics in the treatment of cognitive deficits. The add-on use of substances which directly influence cognitive processes, so-called cognition-enhancing drugs is more promising.

引用

页码：564 / 576

页数：13

共 50 条

[1] Improvement of Cognitive Deficits in the Focus of New Treatment Strategies in Schizophrenia
Falkai, P.
Schmitt, A.
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2014, 82 (03) : 127 - 127
[2] Pharmacological Treatment of Insight Deficits in Schizophrenia
Shad, Mujeeb U.
Moore, Debra
Shepard, Meaghan
Tamminga, Carol
BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 264S - 265S
[3] Treatment of cognitive deficits in schizophrenia
Bowie, CR
Harvey, PD
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (07) : 608 - 613
[4] Treatment of cognitive deficits in schizophrenia - Part 1: Diagnostic and psychological training
Pfueller, U.
Roesch-Ely, D.
Mundt, C.
Weisbrod, M.
NERVENARZT, 2010, 81 (05): : 556 - +
[5] PHARMACOLOGICAL STRATEGIES IN THE TREATMENT OF SCHIZOPHRENIA
RIFKIN, A
PSYCHIATRIC CLINICS OF NORTH AMERICA, 1993, 16 (02) : 351 - 363
[6] PHARMACOLOGICAL TREATMENT OF AROUSAL AND COGNITIVE DEFICITS
WROBLEWSKI, BA
GLENN, MB
JOURNAL OF HEAD TRAUMA REHABILITATION, 1994, 9 (03) : 19 - 42
[7] Cognitive deficits as treatment targets in schizophrenia
Gold, JM
SCHIZOPHRENIA RESEARCH, 2004, 72 (01) : 21 - 28
[8] COGNITIVE DEFICITS IN TREATMENT RESISTANT SCHIZOPHRENIA
Millgate, Edward
Kravariti, Eugenia
MacCabe, James
Hide, Olga
SCHIZOPHRENIA BULLETIN, 2020, 46 : S56 - S57
[9] Metacognitive and social cognitive deficits in schizophrenia. Impact on functioning and treatment strategies
Bruene, Martin
Tas, Cumhur
Brown, Elliot C.
Armgart, Carina
Dimaggio, Giancarlo
Lysaker, Paul
ZEITSCHRIFT FUR PSYCHIATRIE PSYCHOLOGIE UND PSYCHOTHERAPIE, 2013, 61 (04): : 231 - 237
[10] Current Pro-Cognitive Therapeutic Strategies for Improved Pharmacological Treatment in Schizophrenia
Wadenberg, Marie-Louise G.
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (31) : 5045 - 5045

← 1 2 3 4 5 →